A major challenge in Parkinson's disease is the variability in symptoms and rates of
progression, underpinned by heterogeneity of pathological processes. Biomarkers are …

Dementia is a leading cause of disability and death worldwide. At present there is no
disease modifying treatment for any of the most common types of dementia such as …

OBJECTIVE Neurodegenerative diseases are significant health concerns with regard to
morbidity and social and economic hardship around the world. This review describes the …

Background: Multi-arm, multi-stage (MAMS) platform trials can accelerate the identification of
disease-modifying treatments for Parkinson's disease (PD) but there is no current consensus …

Simple Summary The connection between neurodegenerative diseases (NDs) and cancer
has sparked a growing interest in biomedical research. Cancer cells show alterations in …

Background Parkinson's disease (PD) is a common age-related chronic neurodegenerative
disease. There is currently no affordable, effective, and less invasive test for PD diagnosis …

Parkinson's disease is a progressive neurodegenerative disorder that predominantly affects
motor function due to the loss of dopaminergic neurons in the substantia nigra. It presents …

Familial frontotemporal lobar degeneration (FTLD) is a pathologically heterogeneous group
of neurodegenerative diseases with diverse genotypes and clinical phenotypes. Three …

The dopamine transporter (DAT) is closely related to a variety of neurological disorders
including Parkinson's disease (PD) and other neurodegenerative diseases. In vivo imaging …

Background Dual-phase fluorine-18 labeled N-3-fluoropropyl-2β-carbomethoxy-3β-(4-
iodophenyl) nortropane (18F-FP-CIT) positron emission tomography (PET) scans could be …